Boston University researchers validate important roles of iPSCs in regenerativ... (regarding whether the molecular differen...)

Boston University researchers validate important roles of iPSCs in regenerative medicine

Date:5/2/2011

regarding whether the molecular differences found in iPSCs make them as functional for research as ESCs when used in regenerative medicine research.

Kotton and his colleagues set out to understand the limits and potential of iPSCs and whether they should be utilized in research as a basis for the development of potential therapies. They focused their research on the capacity of iPSCs to undergo differentiation in vitro into endodermal tissue.

Working together with the laboratory of Gustavo Mostoslavsky, MD, PhD, assistant professor of medicine at BUSM, the teams of CReM investigators generated their own iPSC lines by reprogramming skin fibroblasts using a special stem cell cassette vector (STEMCC). They interrogated the global gene expression profiles of each cell line during endodermal differentiation and also compared the resulting cells to authentic endoderm from early developing mouse embryos.

"We found that although there are subtle molecular differences between iPSCs and ESCs, their functional potential to differentiate was virtually indistinguishable in vitro," said Kotton, who is a co-director of CReM. "It is important to understand that iPSCs offer many possibilities in regenerative medicine and developmental biology research and may hold the key to future medical treatments for many human diseases."

The next step, said Kotton, is to further differentiate iPSCs into more specific cell types using both mouse and human stem cell lines. CReM currently has 100 stem cell lines from donors with lung-specific diseases that will be used in the research to develop potential treatments against diseases that affect the lungs.

'/>"/>

Contact: Jenny Eriksen
jenny.eriksen@bmc.org
617-638-6841
Boston University Medical Center
Source:Eurekalert

0

GOOD

Page: 1 2
Related medicine news :

1. Boston University researchers find most substance-dependent individuals report poor oral health
2. Boston University School of Medicine professor receives award for quality of care research
3. Boston researchers create SMArt platform architecture, launch $5,000 health app competition
4. Boston Medical Center critical care chief receives grant for lung injury study
5. Boston University School of Medicine professor co-authors first book on deaf ethnicity
6. Boston University School of Medicine awarded grants to improve early detection of lung cancer
7. Boston University researcher lauded for leading-edge lung cancer research efforts
8. Boston, Oct. 21-24: Largest international pediatric oncology conference
9. Boston Medical Center receives 2 grants for integrative medicine research
10. Boston Medical Center research study validates the Boston Bowel Preparation Scale
11. eMindful Provides a New Twist on Chocolate for Members of Boston's Beacon Hill Village

Post Your Comments:

(Date:5/23/2013)... high-risk neuroblastoma a common tumor that forms in the ... drugs. A study published by Cell Press in the ... reveals a new genomic approach to screen for compounds ... to differentiate, or convert from immature cells to more ... identified a compound that causes neuroblastoma cells to differentiate, ...

(Date:5/23/2013)... 2013 Sika Sarnafil , the ... today announced Imperial Roof Systems of Iowa as the ... dedication to quality during the re-roofing of the SuperTarget ... a Sika Sarnafil Elite contractor and one of Target’s ... is committed to sustainable building practices and they are ...

(Date:5/23/2013)... 23, 2013 Diabetes is one of ... become a nuisance when patients are unfortunate enough to ... the National Diabetes Information Clearinghouse at http://goo.gl/QyhCz , ... risk of developing neuropathy which further shrivels the nervous ... such patients. Such nerve damage affects the whole body ...

(Date:5/23/2013)... May 23, 2013 Professional Insurance Plans, ... the nation to celebrate Fibromyalgia Education and Awareness Month. ... chiropractors across the country, the agency feels that it ... of this syndrome that affects an estimated 10 million ... Association , the definition of Fibromyalgia (FM) is, “a ...

(Date:5/23/2013)... 2013 Retül University , the ... announce the formation of a strategic educational partnership with ... to offer a bike industry first “Positioned for Speed” ... for time trial, road and triathlon bike fit. , ... bike fitters with a Retül University, F.I.S.T. or S.I.C.I ...

Breaking Medicine News(10 mins):Health News:New screening approach uncovers potential alternative drug therapies for neuroblastoma 2 Health News:Sika Sarnafil Announces Recycling Project of the Year Winner 2 Health News:Neuropathy Nerve Damage Can Now Be Reversed With Neuracel 2 Health News:Professional Insurance Plans Encourages the Nation to Celebrate Fibromyalgia Education and Awareness Month 2 Health News:Retül, Ero Sports and Alphamantis Partner for Industry First Aero Fit Course 2 Health News:Retül, Ero Sports and Alphamantis Partner for Industry First Aero Fit Course 3

[0] New screening approach uncovers potential alternative drug therapies for neuroblastoma [0] Sika Sarnafil Announces Recycling Project of the Year Winner [0] Neuropathy Nerve Damage Can Now Be Reversed With Neuracel [0] Professional Insurance Plans Encourages the Nation to Celebrate Fibromyalgia Education and Awareness Month [0] Retül, Ero Sports and Alphamantis Partner for Industry First Aero Fit Course

... Mark,s Breathe Easy Tour, Inspires Those with Chronic Lung Disease to ... ... SAN DIEGO, July 24 SeQual Technologies Inc. (SeQual),announced today the ... the American Lung,Association of California and Seton Medical Center intended to ...

... PALO ALTO, Calif., July 24 Horizon Therapeutics, ... Timothy P.,Walbert has been named president, chief executive ... Horizon Therapeutics., "Tim has a long, proven ... the pain and arthritis areas," said George,Tidmarsh, M.D., ...

... Free Diabetes Education and Cholesterol ... Screenings to Race Spectators, INDIANAPOLIS, Ind., July ... and Polymer Technology Systems,Inc. as a partner in the recently announced ... as cholesterol,screenings at the IndyCar Series during the 2008 racing season., ...

... $0.51 from $0.38 in ... - Record diluted EPS increased 30.2 percent to $0.56 from $0.43 in, second-quarter 2007, excluding ... from the ... - Specialty revenues increased 32.6 percent to a record of nearly $2.0 ...

... Mass., July 24 Tepha, Inc., a developer ... resorbable polymers, announced,today that it has appointed John ... and Chief Operating Officer. Mr. Hartnett joins Tepha,following ... which he,progressed from field sales, to marketing management, ...

... BEIJING, July 24 /Xinhua-PRNewswire-FirstCall/ -- China Medical,Technologies, ... a leading China-based,medical device company that develops, ... high intensity focused ultrasound tumor,therapy systems, today ... results for the first quarter ended June ...

SeQual Technologies, American Lung Association of California and Seton Medical Center Partner to Support Survivor & Cyclist in 500-Mile California Ride Horizon Therapeutics Names Timothy P. Walbert as President and CEO Eli Lilly and Company and Vision Racing Sponsor Vision Wellness Tour at the IndyCar Series Across the Country Medco Reports Record Second-Quarter 2008 GAAP Diluted EPS; Reflects Growth of 34.2 Percent; Raises and Narrows 2008 Guidance Tepha Announces Appointment of John Hartnett as Executive Vice President and Chief Operating Officer China Medical Technologies to Announce Financial Results for the First Quarter Ended June 30, 2008 on August 4, 2008

(Date:5/23/2013)... , May 23, 2013 Isis Pharmaceuticals, Inc. ... today announced that management will present a company overview at ... Conference on Thursday, May 30, 2013 at 8:40 a.m. ET ... live audio webcast of the presentation will be available on ... www.isispharm.com . A replay will be available on the ...

(Date:5/23/2013)... TUCSON, Ariz. , May 23, 2013 ... world,s first and only FDA, Health Canada and CE ... announced today that the Glasgow Science Centre in ... visitors annually, is featuring the SynCardia temporary Total ... as part of its $3 million Bodyworks Exhibition, one ...

(Date:5/23/2013)... , May 23, 2013 BioLife Solutions , ... proprietary clinical grade hypothermic storage and ... contract aseptic media manufacturer , today announced its ... Regenerative Medicine Congress 2013 this week in ... ) Dr. Aby J. Mathew, BioLife,s Senior ...

Breaking Medicine Technology:Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference 2 Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 2 Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition 3 BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 2 BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress 3

[0] Isis Pharmaceuticals to Present at the Deutsche Bank 38th Annual dbAccess Health Care Conference [0] Glasgow Science Centre Features SynCardia Total Artificial Heart in $3 Million Exhibition [0] BioLife Solutions Announces Presentation at 8th World Stem Cells & Regenerative Medicine Congress

... - Results Highlight the Potential of ... Algeta ASA (OSE: ALGETA), the ... BC1-04 study reported today it has completed its,comprehensive phase ... for bone metastases in patients with hormone-refractory,prostate cancer (HRPC). ...

... After eight weeks of treatment, RAD001 halted tumor growth ... with chemotherapy - Based on these promising data, Novartis ... advanced gastric cancer patients- Gastric cancer is the second ... of new cases occurring in East AsiaEAST HANOVER, N.J., ...

Cached Medicine Technology:Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer 2 Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer 3 Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer 4 Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer 5 Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer 6 RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 2 RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 3 RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 4 RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 5 RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments 6

Algeta Completes Comprehensive Phase II Clinical Program With Alpharadin for Treating Bone Metastases in Patients With Advanced Prostate Cancer RAD001 Phase II Trial Results Positive in Patients with Advanced Gastric Cancer After Failure of One or More Prior Treatments

... ARUP Laboratories is a national reference laboratory ... research and development. ARUP offers an extensive ... medical tests in clinical and anatomic pathology. ... Laboratories' clients include more than half of ...

... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...

... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...

Medicine Products:

Morphine Quantitation, Serum or Plasma Monoethylglycinerylidide, Urine Moricizine (Ethmozine), Serum or Plasma Mono/Dizygotic Differentiation